UNIVERSITY OF IOWA INSTITUTIONAL CALGB GRANT

此应用程序是为了支持我们参与多- 多学科多机构协作组临床 癌症和急性白血病组B的试验。 自从加入 CALGB 6个月前，我们已经发展成为积极的参与者， 2期和3期研究以及伴随研究均强调 实验室调查 多学科的研究 工作组协助将这些模式汇集在一起， 爱荷华州大学。 合作小组成员资格允许 爱荷华州大学的调查人员在未来5年内将重点放在 创新的小型临床试验（1/2期试验 适合于一个机构），同时参加 对照、随机III期试验在一个 一家医院 此外，CALGB的活动 在爱荷华州大学发起了一项研究， 在受控比较可以 被制造。 我们在下一个资助期的具体目标包括： 何杰金氏和非何杰金氏恶性肿瘤挽救治疗的分组试验 对使用强化化疗的一线治疗耐药的淋巴瘤患者 治疗和自体骨髓移植支持，试验使用 爱荷华州大学免疫学实验室检测 LAK细胞活性和其他免疫学参数，使用 放射增敏剂（如氯尼达明）或支气管内 放射作为放射治疗的创新，以及使用 分化剂（13-顺式视黄酸，维生素D3）基于 爱荷华州大学的I/II期试验结果。 通过 参加团体试验，我们希望能推进 整个CALGB。 通过试点研究（如MOPLEC， 霍奇金病或β-干扰素和IL-2淋巴瘤），我们将 为未来的对照试验开发新的治疗方法。 通过 实验室相关的同伴研究，我们将推进基本的 其他CALGB机构的科学计划。 多- CALGB的学科计划将有助于在未来 5年来，研究员和住院医师的培训， 爱荷华州大学。 通过发展3个分支机构 计划，将促进高质量的多学科癌症护理 在爱荷华州，一个几乎没有大型癌症项目的农村州。 我们的应计费用 每年应该有大约100名来自大学的患者 爱荷华州医院系统和20多名患者每年 从我们的三个分支机构。

This application is to support our participation in the multi- disciplinary and multi-institutional cooperative group clinical trials of Cancer and Acute Leukemia Group B. Since joining the CALGB 6 months ago, we have developed into active participants in both phase 2 and 3 studies and companion studies emphasizing laboratory investigation. The multidisciplinary studies of the group assist in bringing together these modalities at the University of Iowa itself. Cooperative group membership allows the University of Iowa investigators over the next 5 years to focus on innovative, small clinical trials (Phase 1/2 type trials appropriate for a single institution) while participating in controlled, randomized phase III trials not feasible within a single hospital. Further, the activities of the CALGB have initiated research at the University of Iowa utilizing biological response modifiers in a setting in which controlled comparisons can be made. Our specific goals in the next grant period include initiating for the group trials in salvage therapy for Hodgkin's and non-Hodgkin's lymphoma patients resistant to lst line therapies using intensive therapy and autologous bone marrow transplant support, trials using the immunology laboratory of the University of Iowa for assay of LAK cell activity and other immunologic parameters, trials using radiation sensitizers (such as Lonidamine) or endobronchial radiation as innovations in radiation therapy, and trials using differentiating agents (13-cis Retinoic Acid, Vitamin D3) based on phase I/II trial results at the University of Iowa. Through participation in groups trials we hope to advance the programs of the entire CALGB. Through pilot studies (such as MOPLEC for Hodgkin's disease or beta-Interferon and IL-2 for lymphoma) we will help develop newer therapies for future controlled trials. Through laboratory related companion studies, we will advance the basic science programs of other CALGB institutions. The multi- disciplinary programs of the CALGB will contribute over the next 5 years to the training of both fellows and residents at the University of Iowa. Through the development of 3 affiliate programs, quality multidisciplinary cancer care will be fostered in Iowa, a rural state with few large cancer programs. Our accrual should be approximately 100 patients per year from the University of Iowa Hospital system and 20 more patients in addition per year from our 3 affiliates.